

Birzeit Pharmaceutical Company
Consolidated Statement of Financial Position
As of December 31, 2020

	2020 USD	2019 USD
Assets		
Current Assets		
Cash and Cash Equivalent	2,553,639	5,023,746
Fixed Deposits at Banks	1,500,000	1,500,000
Accounts Receivable, Net	24,013,458	24,636,307
Inventory	12,190,134	12,358,740
Financial Investments through P&L	8,637,123	7,358,593
Other Debit Balances	1,218,803	137,913
Total Current Assets	50,113,157	51,015,299
Non Current Assets		
Deferred Tax Assets	1,033,989	985,139
Financial Investments through OCI	19,698,876	21,832,382
Investment in Affiliates	-	502,332
Investment Property	6,143,519	4,511,611
Property, Plant and Equipment, Net	22,070,380	19,281,429
Total Non Current Assets	48,946,764	47,112,893
Total Assets	99,059,921	98,128,192
Owners' Equity and Liability		
Current Liabilities		
Payables and other Credit Balances	6,154,496	5,615,217
Allowance for Income Tax	-	-
Bank Loans - Short Term Portion	1,166,664	1,166,664
Total Current Liabilities	7,321,160	6,781,881
Non Current Liabilities		
Reserve for Employees' End of Service	9,972,995	9,441,209
Bank Loans - Long Term Portion	2,034,728	3,201,392
Total Liability	19,328,883	19,424,482
Owners' Equity		
Share capital	19,002,401	19,002,401
Treasury stocks	(138,900)	(136,848)
	18,863,501	18,865,553
Statutory Reserve	4,750,600	4,750,600
Optional Reserve	5,158,810	5,158,810
Special Reserve	20,000,000	20,000,000
Retained Earnings	31,632,153	28,443,690
Cumulative change in fair value	(1,605,954)	611,529
Cash Flow hedge reserve	(387,048)	-
Financial statements currency translation variance	462,459	261,881
Equity Attributable to Owners of the Parent Company	78,874,521	78,092,063
Non Controlling Interests	856,517	611,647
Total Equity	79,731,038	78,703,710
Total Equity and Liability	99,059,921	98,128,192



Mr. Talal Nassereddin
Chairman

Mr. Firas Nassereddin
Board Member



Birzeit Pharmaceutical Company
Consolidated Statement of Income
For the Year Ended December 31, 2020

	2020	2019
	USD	USD
Sales	35,854,785	34,575,383
Cost of Goods sold	<u>(22,423,426)</u>	<u>(19,749,768)</u>
Gross profit	13,431,359	14,825,615
Sales Expenses	(2,093,619)	(2,316,019)
Marketing Expenses	(1,159,711)	(1,138,752)
General and Administrative Expenses	(3,024,991)	(2,620,148)
Loan interest	(238,725)	(128,737)
Expected credit loss	<u>(271,054)</u>	<u>(922,506)</u>
Gross profit from operating activities	6,643,259	7,699,453
Gain from Sale and Revaluation of Financial Investments	1,084,421	1,395,457
Gain from Sale of Investment Property	-	303,800
Gain from Revaluation of Investment Property	-	1,702,571
(Loss) from Revaluation of Investment in Affiliates	-	(1,250,379)
Revaluation of Ownership Interest in Affiliate Company	244,505	-
(Loss) from Acquisition of an Additional shares in a Subsidiary	(118,826)	-
Gain Difference of Currency	227,525	380,748
Other Revenues	<u>70,000</u>	<u>61,089</u>
Net Income for the Year Before Taxes	8,150,884	10,292,739
Income tax on previous years	(523)	(82,791)
Income tax on current year	(823,728)	(768,820)
Deferred tax benefits	48,850	109,514
Net Income After Taxes	7,375,483	9,550,642
Attributable to:		
Owners of the Parent Company	7,368,991	9,524,645
Non Controlling Interests	<u>6,492</u>	<u>25,997</u>
	7,375,483	9,550,642
Earnings Per Share for Parent Company	0.39	0.50



Mr. Talal Nassereddin
Chairman

Mr. Firas Nassereddin
Board Member



Birzeit Pharmaceutical Company
Consolidated Statement of Other Comprehensive Income
For the Year Ended December 31, 2020

	2020 USD	2019 USD
Net Income After Taxes	7,375,483	9,550,642
Other comprehensive income		
Items that will not be re-classified subsequently to profit or loss		
Change in fair value for financial assets	<u>(2,217,483)</u>	<u>(693,932)</u>
	(2,217,483)	(693,932)
Items that may be re-classified subsequently to profit or loss		
Financial statements currency translation variance	160,285	237,340
(Loss) Fair value of cash hedging contracts during the year	<u>(387,048)</u>	<u>-</u>
	(226,763)	237,340
Other comprehensive (loss)	(2,444,246)	(456,592)
Total other comprehensive for the year	<u>4,931,237</u>	<u>9,094,050</u>
Attributable to:		
Owners of the Company	4,965,038	9,068,053
Non Controlling Interests	<u>(33,801)</u>	<u>25,997</u>
	<u>4,931,237</u>	<u>9,094,050</u>

Calafaddun



Birzeit Pharmaceutical Company
Consolidated Statement of Change in Owner's Equity
For the Year Ended December 31, 2020

	Share Capital USD	Statutory Reserve USD	Optional Reserve USD	Special Reserve USD	Retained Earnings USD	Cash Flow Hedge Reserve	Cumulative Change in Fair Value	Financial Statements Currency Translation Variance	Treasury Shares	Equity Attributable to Owners of the Company USD	Equity Attributable -to the non controlling interest USD	Total Equity USD
Balance as of January 1, 2018	19,002,401	4,750,600	5,158,810	20,000,000	21,769,405	-	1,305,461	24,541	(132,907)	71,878,311	585,650	72,463,961
Income for the year	-	-	-	-	9,524,645	-	(693,932)	-	-	9,524,645	25,997	9,550,642
Other comprehensive income	-	-	-	-	-	-	-	237,340	-	(456,592)	-	(456,592)
Total other comprehensive for the year	-	-	-	-	9,524,645	-	(693,932)	237,340	-	9,068,053	25,997	9,094,050
Dividends paid	-	-	-	-	(2,850,360)	-	-	-	-	(2,850,360)	-	(2,850,360)
Change in Treasury Shares	-	-	-	-	-	-	-	-	(3,941)	(3,941)	-	(3,941)
Balance as of December 31, 2019	19,002,401	4,750,600	5,158,810	20,000,000	28,443,690	-	611,529	261,881	(136,848)	78,092,063	611,647	78,703,710
Balance as of January 1, 2019	19,002,401	4,750,600	5,158,810	20,000,000	28,443,690	-	611,529	261,881	(136,848)	78,092,063	611,647	78,703,710
Resulted from Acquisition of a Subsidiary	-	-	-	-	-	-	-	-	-	-	-	-
Income for the year	-	-	-	-	7,368,991	-	-	-	-	7,368,991	6,492	7,375,483
Other comprehensive income	-	-	-	-	-	(387,048)	(2,217,483)	200,578	-	(2,403,953)	(40,293)	(2,444,246)
Total other comprehensive for the year	-	-	-	-	7,368,991	(387,048)	(2,217,483)	200,578	-	4,965,038	(33,801)	4,931,237
Dividends paid	-	-	-	-	(4,180,528)	-	-	-	-	(4,180,528)	-	(4,180,528)
Change in Treasury Shares	-	-	-	-	-	-	-	-	(2,052)	(2,052)	-	(2,052)
Balance as of December 31, 2020	19,002,401	4,750,600	5,158,810	20,000,000	31,632,153	(387,048)	(1,605,954)	462,459	(138,900)	78,874,521	856,517	79,731,038

Abdullah



Birzeit Pharmaceutical Company
Consolidated Statement of Cash Flows
For the Year Ended December 31, 2020

	2020	2019
	USD	USD
Operating Activities		
Net profit before tax	8,150,884	10,292,739
Adjustments:		
Depreciation	1,685,551	1,608,410
Expected Credit Loss	271,054	922,506
Loss from Revaluation of Investment in Affiliates	-	1,250,379
(Gain) from Revaluation of Investment Property	-	(1,702,571)
(Gain) from Sale of Investment Property	-	(303,800)
Revaluation of previous share in affiliate company	(244,505)	-
Loss from acquisition of additional share in a subsidiary	118,826	-
(Gain) from sale and valuation of financial assets	(749,516)	(452,068)
Foreign currency difference	134,602	(54,547)
Provision for end of service indemnity	1,091,732	1,201,544
Cash flow before changes in operating assets and liabilities	10,458,628	12,762,592
Decrease in accounts receivables	1,408,568	953,841
Decrease (increase) in inventory	225,902	(645,405)
(Increase) in other debit balances	(1,645,920)	(8,100)
(Decrease) in other credit balances	(4,263,029)	(416,487)
Cash from operating activities	6,184,149	12,646,441
Tax paid	(523)	(1,304,271)
Employee's end of service benefits paid	(593,016)	(282,662)
Net cash generated from operating activities	5,590,610	11,059,508
Investing Activities		
Purchase of financial assets	(1,818,928)	(6,167,409)
(Increase) in fixed deposits at banks	-	(1,500,000)
Proceed from sale of financial assets	1,240,681	4,125,169
Cash paid to acquire PetraPharm	(199,507)	-
Purchase of Investment Property	(1,916,800)	-
Proceed from sale of Investment Property	284,892	850,552
Purchase of property, plant and equipment	(502,389)	(4,218,012)
Net cash (used in) investing activities	(2,912,051)	(6,909,700)
Financing Activities		
Increase in bank loans	-	2,500,000
Repayments from bank loans	(1,166,664)	(819,444)
Change in treasury shares	(2,052)	(3,941)
Dividends paid	(4,180,528)	(2,850,360)
Net cash generated from financing activities	(5,349,244)	(1,173,745)
Net (decrease) increase in cash and cash equivalent	(2,670,685)	2,976,063
Financial statements currency translation variance	200,578	237,340
Cash and cash equivalent at the beginning of the year	5,023,746	1,810,343
Cash and cash equivalent at the End of the year	2,553,639	5,023,746
Non-Cash Movements:		
Clearance with the Ministry of Health on income tax and VAT	(1,703,788)	-
Net assets acquired from the subsidiary	746,837	-
Cumulative change in fair value reserve through OCI	2,217,483	693,932
Cash flow hedge reserve	387,048	-
Income tax receivables transferred to other debit balances	(880,583)	-
	766,997	693,932

Abdullah